NZ787392A - Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 - Google Patents
Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2Info
- Publication number
- NZ787392A NZ787392A NZ787392A NZ78739217A NZ787392A NZ 787392 A NZ787392 A NZ 787392A NZ 787392 A NZ787392 A NZ 787392A NZ 78739217 A NZ78739217 A NZ 78739217A NZ 787392 A NZ787392 A NZ 787392A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- bdca2
- antibody
- amino acid
- set forth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 | |
| NZ747504A NZ747504A (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ787392A true NZ787392A (en) | 2025-08-29 |
Family
ID=58672794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ787392A NZ787392A (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 |
| NZ747504A NZ747504A (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ747504A NZ747504A (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190284281A1 (enExample) |
| EP (1) | EP3448425A1 (enExample) |
| JP (3) | JP7045327B2 (enExample) |
| KR (5) | KR20220028150A (enExample) |
| CN (2) | CN116850282A (enExample) |
| AU (2) | AU2017258191B2 (enExample) |
| BR (1) | BR112018072125A2 (enExample) |
| CA (1) | CA3022116A1 (enExample) |
| CO (1) | CO2018012506A2 (enExample) |
| EA (1) | EA201892443A1 (enExample) |
| IL (2) | IL262514B2 (enExample) |
| MA (1) | MA44763A (enExample) |
| MX (3) | MX2018012945A (enExample) |
| NZ (2) | NZ787392A (enExample) |
| PH (1) | PH12018502278A1 (enExample) |
| WO (1) | WO2017189827A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3672981A4 (en) * | 2017-08-22 | 2021-09-15 | Biogen MA Inc. | PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT |
| EP4559485A3 (en) | 2018-07-19 | 2025-08-06 | Ichnos Sciences S.A. | Liquid antibody formulation |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| IL303279A (en) | 2020-12-03 | 2023-07-01 | Biogen Ma Inc | Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus |
| EP4385525A1 (en) | 2021-08-09 | 2024-06-19 | Inventera Inc. | Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| WO2024140838A1 (zh) * | 2022-12-28 | 2024-07-04 | 映恩生物制药（苏州）有限公司 | 抗bdca2抗体-药物偶联物及其用途 |
| WO2025067469A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2335725T3 (en) * | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| MX363407B (es) * | 2012-12-10 | 2019-03-22 | Biogen Ma Inc | Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos. |
-
2017
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Ceased
- 2017-04-27 NZ NZ787392A patent/NZ787392A/en unknown
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active Active
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 NZ NZ747504A patent/NZ747504A/en unknown
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 KR KR1020257018429A patent/KR20250088784A/ko active Pending
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 BR BR112018072125-5A patent/BR112018072125A2/pt active Search and Examination
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 KR KR1020247035142A patent/KR20240159012A/ko not_active Ceased
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Ceased
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en not_active Ceased
-
2018
- 2018-10-22 IL IL262514A patent/IL262514B2/en unknown
- 2018-10-23 MX MX2025000037A patent/MX2025000037A/es unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
-
2025
- 2025-02-21 US US19/060,474 patent/US20250289895A1/en active Pending
- 2025-06-17 IL IL321561A patent/IL321561A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ787392A (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 | |
| EP3991745A1 (en) | Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof | |
| SG174779A1 (en) | Anti-cd3 antibody formulations | |
| KR20220027265A (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| US20230391879A1 (en) | Caninized antibodies to canine interleukin-31 receptor alpha | |
| CN113453719A (zh) | 包含抗cd47抗体的制剂及其制备方法和用途 | |
| EP4151233A1 (en) | Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof | |
| JP2025142195A (ja) | 抗ｐｄ－１／ｈｅｒ２二重特異性抗体を含む製剤及びその調製方法と使用 | |
| CN114053403A (zh) | 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途 | |
| US20250346657A1 (en) | Caninized and felinized antibodies to human ngf | |
| JP6592600B2 (ja) | 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用 | |
| CN110506058A (zh) | 免疫激动剂的施用路径 | |
| WO2025119304A1 (en) | Heterodimeric proteins against il-12 receptor | |
| TW202428610A (zh) | 標靶ＴＮＦα和ＩＬ－２３的抗體及其用途 | |
| JP2022539088A (ja) | 抗ｌａｇ‐３抗体を含む製剤、その調製方法及び使用 | |
| CN118401549A (zh) | 人ngf的犬源化和猫源化抗体 | |
| HK40059591A (en) | Preparations containing anti-cd47 antibody, and preparation method and use therefor | |
| BR122024003611A2 (pt) | Composições farmacêuticas, anticorpo anti-bdca2, uso do mesmo, e seringa ou bomba | |
| EA043069B1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови |